Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Untreated Chronic Lymphocytic Leukemia
Conditions
Brief summary
This phase II trial studies how well ruxolitinib phosphate works in treating patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Detailed description
PRIMARY OBJECTIVES: I. To determine the effect of ruxolitinib phosphate (ruxolitinib) in patients with high-risk chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who do not require anti-neoplastic therapy according to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 recommendations and were either previously untreated or treated with Ibrutinib for less than 3 months and were deemed Ibrutinib intolerant: Ia. On disease burden. Ib. The rate of complete response (CR) and partial response (PR) as assessed by the IWCLL 2008 response criteria. SECONDARY OBJECTIVES: I. To evaluate the time to next treatment of high-risk CLL/SLL who do not require anti-neoplastic therapy according to the IWCLL 2008 recommendations. OUTLINE: Patients receive ruxolitinib phosphate orally (PO) twice daily (BID). Treatment continues for up to 3 years in the absence of disease progression or unacceptable toxicity. Treatment beyond 3 years may be permitted after discussion with the principal investigator. After completion of study treatment, patients are followed up at 30 days.
Interventions
DRUGRuxolitinib
Given PO
Given PO
Sponsors
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Inclusion: 1. Subjects who are able to understand and sign an informed consent document. 2. Subjects 18 years of age or older. 3. Subjects must be diagnosed with CLL/SLL and do not meet the IWCLL criteria for treatment 4. Patients should be previously untreated or have only been treated with single agent ibrutinib therapy for a period of \< 3 months and were deemed ibrutinib intolerant. 5. Patients whose expected time to CLL/SLL treatment, according to our nomogram posted on the leukemia protocol priority list, is four years of less. 6. Subjects with hemoglobin values at the screening visit equal to or greater than 12.0 g/dL. 7. Subjects with a platelet count of at least 100 x10\^9 at the screening visit. 8. Subjects with an absolute neutrophil count (ANC) of equal to or higher than 0.5 x10\^9 at the screening visit. 9. Subject who are willing to undergo a bone marrow aspiration and biopsy and CT scan for disease burden assessment. 10. Patient who are capable to return to MD Anderson Cancer Center (MDACC) for follow-up 11. Subjects with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 12. Patient must be capable of swallowing the Ruxolotinib capsules (tablets). Exclusion: 1. Females who are pregnant or are currently breastfeeding. 2. Subjects of childbearing potential who are unwilling to take appropriate precautions (throughout the study from screening including 30 days after discontinuation of the study drug) to avoid becoming pregnant or fathering a child. A) Females of non-childbearing potential are defined as women who (a) are equal to or greater than 55 years of age with history of amenorrhea for 1 year, OR (b) are surgically sterile for at least 3 months. B) For females of childbearing potential, or for males, appropriate precautions are those that are at least 99% effective in preventing the occurrence of pregnancy. These methods should be communicated to the subjects and their understanding confirmed: a) Double barrier methods; b) Condom with spermicide in conjunction with use of an intrauterine device (IUD); c) Condom with spermicide in conjunction with use of a diaphragm; d) Oral, injectable, or implanted contraceptives; e) Tubal ligation or vasectomy (surgical sterilization) 3. Subjects with recent history of inadequate bone marrow reserve as demonstrated by previous transfusions except for acute blood loss (e.g. surgery) in the month prior to screening. 4. Subjects with inadequate liver or renal function at screening and baseline visits: A) Alanine aminotransferase (ALT) \> 2.5x Upper limit of normal (ULN). B) Modification of Diet in Renal Disease (MDRD) calculated GFR \< 30 mL/min 5. Subjects with active uncontrolled infection or who are HIV positive (Subjects with acute infections requiring treatment should delay screening/enrollment until the course of therapy has been completed and the event is considered controlled). 6. Subjects with a history of or a current malignancy except for treated basal or squamous carcinomas of the skin completely resected. 7. Subjects with clinically significant uncontrolled cardiac disease. 8. Subjects being treated concurrently with any prohibited medications, including investigational medication, rifampin, St. John's wort, and potent CYP3A4 inhibitors (excluding ketoconazole) unless continuation of such medications are determined by the investigator to be in the best interest of the patient. Refer to protocol section 2.2.12 for more details. 9. Subjects who have previously received JAK inhibitor therapy 10. Subjects with active alcohol or drug addiction that would interfere with their ability to comply with the study requirements. 11. Subjects with any concurrent condition that, in the Investigator's opinion, would jeopardize the safety of the subject or compliance with the protocol. 12. Subjects who have unknown transfusion history. 13. Patients who cannot comply with the study requirements.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Participants With a Clinical Response | Up to 6 months after initiation of therapy | Clinical response will be assessed based on physical examination, complete blood count (CBC), a bone marrow aspiration, a whole body CT scan to be done at screening and 6 + 2 months in accordance with the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guidelines (Hallek et al., 2008) |
| Number of Participants With Change of Tumor Burden | 6 months after initiation of therapy | Tumor burden will be assessed by bone marrow aspiration, whole body CT scan at screening and 6 months. |
| Participants With a Response | Up to 30 days | Response Rate is Complete Response (CR) or Partial Response (PR). CR is absence of Lymphadenopathy, Hepatomegaly or Splenomegaly, lymphocytes \< 4000/ul, normocellular, \<30% lymphocytes, no B-lymphoid nodules, Platelets \> 100,000/ul, hemoglobin \>11.0 g/dl and Neutrophils \>1500/ul. PR is \>/= 50% decrease in lymphadenopathy, hepatomegaly, splenomegaly and Blood Lymphocytes from baseline, 50% reduction in marrow infiltrate or B-lymphoid nodules. Platelet count \> 100,000/ul, Hemoglobin \> 11 g/dl and Neutrophils \>1500/ul or increase \>/= 50% of all over base. |
| Time to Next Treatment | Up to 30 days | Number of months to subsequent therapy per patient. |
Countries
United States
Participant flow
Recruitment details
Recruitment Period: March 2017 to June 2019
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Ruxolitinib Phosphate) Patients receive ruxolitinib phosphate PO BID. Treatment continues for up to 3 years in the absence of disease progression or unacceptable toxicity. Treatment beyond 3 years may be permitted after discussion with the principal investigator.
Ruxolitinib: Given PO
Ruxolitinib Phosphate: Given PO | 1 |
| Total | 1 |
Baseline characteristics
| Characteristic | Treatment (Ruxolitinib Phosphate) |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 1 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 0 Participants |
| Region of Enrollment United States | 1 Participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 1 |
| other Total, other adverse events | 1 / 1 |
| serious Total, serious adverse events | 0 / 1 |
Outcome results
Primary
Number of Participants With Change of Tumor Burden
Tumor burden will be assessed by bone marrow aspiration, whole body CT scan at screening and 6 months.
Time frame: 6 months after initiation of therapy
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Ruxolitinib Phosphate) | Number of Participants With Change of Tumor Burden | 0 Participants |
Primary
Participants With a Clinical Response
Clinical response will be assessed based on physical examination, complete blood count (CBC), a bone marrow aspiration, a whole body CT scan to be done at screening and 6 + 2 months in accordance with the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guidelines (Hallek et al., 2008)
Time frame: Up to 6 months after initiation of therapy
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Ruxolitinib Phosphate) | Participants With a Clinical Response | 0 Participants |
Primary
Participants With a Response
Response Rate is Complete Response (CR) or Partial Response (PR). CR is absence of Lymphadenopathy, Hepatomegaly or Splenomegaly, lymphocytes \< 4000/ul, normocellular, \<30% lymphocytes, no B-lymphoid nodules, Platelets \> 100,000/ul, hemoglobin \>11.0 g/dl and Neutrophils \>1500/ul. PR is \>/= 50% decrease in lymphadenopathy, hepatomegaly, splenomegaly and Blood Lymphocytes from baseline, 50% reduction in marrow infiltrate or B-lymphoid nodules. Platelet count \> 100,000/ul, Hemoglobin \> 11 g/dl and Neutrophils \>1500/ul or increase \>/= 50% of all over base.
Time frame: Up to 30 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Ruxolitinib Phosphate) | Participants With a Response | 0 Participants |
Primary
Time to Next Treatment
Number of months to subsequent therapy per patient.
Time frame: Up to 30 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Ruxolitinib Phosphate) | Time to Next Treatment | 0 Months |